Insider Trading disclosures for Merck & Co Inc

The latest disclosure was made by Jannie Oosthuizen in Merck & Co Inc where a trade of 8,500 Common Stock done at an average price of $84.1 was reported to US exchanges on Feb. 19, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Jannie Oosthuizen	President, U.S. Market	Sale of securities on an exchange or to another person at price $ 84.09 per share.	19 Feb 2025	8,500	30,705 (0%)	0%	84.1	714,745	Common Stock
David Michael Williams	EVP,Chief Info&Digital Officer	Sale of securities on an exchange or to another person at price $ 85.34 per share.	13 Feb 2025	6,000	24,123 (0%)	0%	85.3	512,057	Common Stock
Jannie Oosthuizen	President, U.S. Market	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	08 Feb 2025	13,002	0	-		-	Restricted Stock Unit
Jannie Oosthuizen	President, U.S. Market	Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.28 per share.	08 Feb 2025	6,404	39,205 (0%)	0%	87.3	558,941	Common Stock
Jannie Oosthuizen	President, U.S. Market	Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.28 per share.	08 Feb 2025	13,002	45,609 (0%)	0%	87.3	1,134,815	Common Stock
Inge G. Thulin	Director	Purchase of securities on an exchange or from another person at price $ 88.28 per share.	06 Feb 2025	2,832	2,932 (0%)	0%	88.3	250,000	Common Stock
Cristal N. Downing	Chief Comm. & Public Afrs Ofcr	Sale of securities on an exchange or to another person at price $ 88.76 per share.	06 Feb 2025	2,361	7,085 (0%)	0%	88.8	209,551	Common Stock
Douglas M. Baker	Director	Purchase of securities on an exchange or from another person at price $ 88.50 per share.	05 Feb 2025	15,000	16,000 (0%)	0%	88.5	1,327,500	Common Stock
Caroline A. Litchfield	EVP & CFO	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	23,432	74,340 (0%)	0%	97.9	2,294,930	Common Stock
David Michael Williams	EVP,Chief Info&Digital Officer	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	10,246	30,123 (0%)	0%	97.9	1,003,493	Common Stock
Dean Y. Li	Executive VP & President, MRL	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	32,621	79,592 (0%)	0%	97.9	3,194,901	Common Stock
Cristal N. Downing	Chief Comm. & Public Afrs Ofcr	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	9,446	9,446 (0%)	0%	97.9	925,141	Common Stock
Jannie Oosthuizen	President, U.S. Market	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	8,664	32,607 (0%)	0%	97.9	848,552	Common Stock
Dalton E. Smart	SVP Fin. - Global Controller	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	2,586	7,014 (0%)	0%	97.9	253,273	Common Stock
Richard R. DeLuca	EVP&Pres, Merck Animal Heallth	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	25,438	178,992 (0%)	0%	97.9	2,491,398	Common Stock
Robert M. Davis	Director, Chairman, CEO & President	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	95,275	443,601 (0%)	0%	97.9	9,331,234	Common Stock
Sanat Chattopadhyay	Exe V-P & Pres. MMD	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	28,136	78,758 (0%)	0%	97.9	2,755,640	Common Stock
Chirfi Guindo	Chief Marketing Officer	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	28,158	69,143 (0%)	0%	97.9	2,757,795	Common Stock
Jennifer Zachary	EVP, General Counsel	Grant, award, or other acquisition of securities at price $ 97.94 per share.	27 Jan 2025	25,423	55,285 (0%)	0%	97.9	2,489,929	Common Stock
Thomas Henry Glocer	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Sep 2024	429	97,074	-		-	Phantom Stock
Mary Ellen Coe	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Sep 2024	264	23,574	-		-	Phantom Stock
Christine E. Seidman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Sep 2024	71	14,977	-		-	Phantom Stock
Chirfi Guindo	Chief Marketing Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.20 per share.	05 Aug 2024	36,901	57,781 (0%)	0%	115.2	4,250,995	Common Stock
Chirfi Guindo	Chief Marketing Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Aug 2024	36,901	36,903	-		-	Restricted Stock Unit
Chirfi Guindo	Chief Marketing Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.20 per share.	05 Aug 2024	17,412	40,369 (0%)	0%	115.2	2,005,862	Common Stock
Thomas Henry Glocer	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	28 Jun 2024	393	96,063	-		-	Phantom Stock
Mary Ellen Coe	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	28 Jun 2024	242	23,169	-		-	Phantom Stock
Christine E. Seidman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	28 Jun 2024	65	14,815	-		-	Phantom Stock
Douglas M. Baker	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	6,281	-		-	Phantom Stock
Inge G. Thulin	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	21,228	-		-	Phantom Stock
Patricia F. Russo	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	53,951	-		-	Phantom Stock
Thomas Henry Glocer	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	95,669	-		-	Phantom Stock
Pamela J. Craig	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	28,233	-		-	Phantom Stock
Risa J. Lavizzo-Mourey	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	12,120	-		-	Phantom Stock
Kathy J. Warden	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	12,252	-		-	Phantom Stock
Paul B. Rothman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	28,233	-		-	Phantom Stock
Mary Ellen Coe	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	22,927	-		-	Phantom Stock
Christine E. Seidman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	14,749	-		-	Phantom Stock
Stephen L. Mayo	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 May 2024	1,752	9,379	-		-	Phantom Stock
Richard R. DeLuca	EVP&Pres, Merck Animal Heallth	Payment of exercise price or tax liability using portion of securities received from the company at price $ 127.51 per share.	04 May 2024	13,360	150,359 (0%)	0%	127.5	1,703,534	Common Stock
Richard R. DeLuca	EVP&Pres, Merck Animal Heallth	Exercise or conversion of derivative security received from the company (such as an option) at price $ 127.51 per share.	04 May 2024	27,126	163,719 (0%)	0%	127.5	3,458,836	Common Stock
Richard R. DeLuca	EVP&Pres, Merck Animal Heallth	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	04 May 2024	27,126	0	-		-	Restricted Stock Unit
Michael A Klobuchar	EVP - Chief Strategy Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 127.51 per share.	04 May 2024	437	23,621 (0%)	0%	127.5	55,722	Common Stock
Michael A Klobuchar	EVP - Chief Strategy Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 127.51 per share.	04 May 2024	887	24,058 (0%)	0%	127.5	113,101	Common Stock
Michael A Klobuchar	EVP - Chief Strategy Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	04 May 2024	887	0	-		-	Restricted Stock Unit
Jannie Oosthuizen	President, U.S. Market	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	04 May 2024	912	0	-		-	Restricted Stock Unit
Jannie Oosthuizen	President, U.S. Market	Payment of exercise price or tax liability using portion of securities received from the company at price $ 127.51 per share.	04 May 2024	450	23,820 (0%)	0%	127.5	57,380	Common Stock
Jannie Oosthuizen	President, U.S. Market	Exercise or conversion of derivative security received from the company (such as an option) at price $ 127.51 per share.	04 May 2024	912	24,270 (0%)	0%	127.5	116,289	Common Stock
Dalton E. Smart	SVP Fin. - Global Controller	Exercise or conversion of derivative security received from the company (such as an option) at price $ 128.26 per share.	03 May 2024	516	3,433 (0%)	0%	128.3	66,182	Common Stock
Dalton E. Smart	SVP Fin. - Global Controller	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	03 May 2024	612	0	-		-	Restricted Stock Unit

Showing 1 to 50 of 500 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

29.64% Fall from 52W High

Insider Trading disclosures for Merck & Co Inc

The latest disclosure was made by Jannie Oosthuizen in Merck & Co Inc where a trade of 8,500 Common Stock done at an average price of $84.1 was reported to US exchanges on Feb. 19, 2025.

Screeners based on Insider Trading and SAST parameters